There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC. Method of administration Intravenous injection use. Areas of interest Ways to collaborate How? In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Name of the medicinal product 2.

Author:Mora Tugal
Language:English (Spanish)
Published (Last):11 June 2006
PDF File Size:3.64 Mb
ePub File Size:4.42 Mb
Price:Free* [*Free Regsitration Required]

The white, freeze-dried powder contains terlipressin acetate. Glypressin Injection is used in the treatment of bleeding oesophageal varices. Bleeding oesophageal varices are enlarged blood vessels that form in the stomach or oesophagus as a complication of liver disease. They may burst and bleed and this is a serious and life-threatening condition. When injected into the bloodstream, the active ingredient, terlipressin acetate is broken down to release a substance called lysine vasopressin.

This acts on the walls of the blood vessels, causing them to narrow and restrict the blood flow to the affected veins so that bleeding is reduced. If any of the above apply to you or you are not sure talk to your doctor or nurse before you are given Glypressin.

Taking with other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. The usual dose of Glypressin Injection in acute bleeding from oesophageal varices is 2mg followed by 1 or 2 mg every 4 to 6 hours until bleeding is controlled, up to a maximum of 48 hours. During treatment, your blood pressure, serum sodium and potassium and fluid balance will normally be monitored constantly.

Keep container in the outer carton. Do not use after the expiry date marked on the packaging. Hydrochloric acid is added to adjust the acidity to make it suitable for injection.

Marketing Authorisation Holder:.



As the situation regarding COVID novel coronavirus disease is evolving rapidly, Ferring is committed to following appropriate global, regional and local medical authority guidance to prevent infection spread and to keep patients, our employees and their families safe. In line with the current positions from scientific societies on patients seeking or undergoing fertility treatment, including from the European Society of Human Reproduction and Embryology ESHRE and the American Society of Reproductive Medicine ASRM , Ferring is now working to temporarily halt recruitment or postpone our clinical trials in fertility as necessary in impacted countries. In addition to policies to protect our employees and prevent infection spread, we have also put in place plans to avoid disruption in manufacturing and ensure continuity of supply of our treatments to doctors and patients around the world. However, we unfortunately cannot rule out a future impact on our business as the situation is rapidly evolving.



To view the changes to a medicine you must sign up and log in. Name of the medicinal product 2. Hyponatraemia if fluid not monitored. Gastroenterology — Ferring Corporate Pregnancy, puerperium and perinatal conditions.




Related Articles